182 related articles for article (PubMed ID: 34117374)
1. Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation.
Fu YH; Ou DL; Yang YR; Su KW; Chen CY; Tien HF; Lai ZS; Shen CJ; Chien HF; Lin LI
Cancer Gene Ther; 2022 Jun; 29(6):784-792. PubMed ID: 34117374
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of PI3K and activation of MAPK p38 signaling pathways trigger erythroid alternative splicing switch of 4.1R pre-mRNA in DMSO-induced erythroleukemia cells.
Breig O; Théoleyre-Schaal O; Baklouti F
Cell Signal; 2013 Dec; 25(12):2453-61. PubMed ID: 23993958
[TBL] [Abstract][Full Text] [Related]
4. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways.
Witt O; Sand K; Pekrun A
Blood; 2000 Apr; 95(7):2391-6. PubMed ID: 10733512
[TBL] [Abstract][Full Text] [Related]
5. Cytarabine-Resistant
Ko YC; Hu CY; Liu ZH; Tien HF; Ou DL; Chien HF; Lin LI
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862120
[TBL] [Abstract][Full Text] [Related]
6. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of transglutaminase 2 accelerates the erythroid differentiation of human chronic myelogenous leukemia K562 cell line through PI3K/Akt signaling pathway.
Kang SK; Lee JY; Chung TW; Kim CH
FEBS Lett; 2004 Nov; 577(3):361-6. PubMed ID: 15556610
[TBL] [Abstract][Full Text] [Related]
8. A multifunctional 5-aminolevulinic acid derivative induces erythroid differentiation of K562 human erythroleukemic cells.
Berkovitch-Luria G; Yakobovitch S; Weitman M; Nudelman A; Rozic G; Rephaeli A; Malik Z
Eur J Pharm Sci; 2012 Aug; 47(1):206-14. PubMed ID: 22705251
[TBL] [Abstract][Full Text] [Related]
9. Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells.
Kohmura K; Miyakawa Y; Kawai Y; Ikeda Y; Kizaki M
J Cell Physiol; 2004 Mar; 198(3):370-6. PubMed ID: 14755542
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ
Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
12. ETV6 Regulates Hemin-Induced Erythroid Differentiation of K562 Cells through Mediating the Raf/MEK/ERK Pathway.
Li Z; Sun MZ; Lv X; Guo C; Liu S
Biol Pharm Bull; 2022; 45(3):250-259. PubMed ID: 35228392
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone Inhibits JAK/STAT and PI3K/Akt/ mTOR Signaling Pathways in MV4-11 and K562 Myeloid Leukemia Cells.
Al-Rawashde FA; Al-Wajeeh AS; Vishkaei MN; Saad HKM; Johan MF; Taib WRW; Ismail I; Al-Jamal HAN
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145344
[TBL] [Abstract][Full Text] [Related]
14. Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells.
Missiroli S; Etro D; Buontempo F; Ye K; Capitani S; Neri LM
Int J Biochem Cell Biol; 2009 Mar; 41(3):570-7. PubMed ID: 18694847
[TBL] [Abstract][Full Text] [Related]
15. Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK.
Brózik A; Casey NP; Hegedus C; Bors A; Kozma A; Andrikovics H; Geiszt M; Német K; Magócsi M
Ann N Y Acad Sci; 2006 Dec; 1090():344-54. PubMed ID: 17384279
[TBL] [Abstract][Full Text] [Related]
16. Depletion of glutamine enhances sodium butyrate-induced erythroid differentiation of K562 cells.
Canh Hiep N; Kinohira S; Furuyama K; Taketani S
J Biochem; 2012 Dec; 152(6):509-19. PubMed ID: 22923740
[TBL] [Abstract][Full Text] [Related]
17. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
[TBL] [Abstract][Full Text] [Related]
18. Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents.
Leger DY; Liagre B; Beneytout JL
Apoptosis; 2006 Oct; 11(10):1747-60. PubMed ID: 16927021
[TBL] [Abstract][Full Text] [Related]
19. Functional regulation of pre-B-cell leukemia homeobox interacting protein 1 (PBXIP1/HPIP) in erythroid differentiation.
Manavathi B; Lo D; Bugide S; Dey O; Imren S; Weiss MJ; Humphries RK
J Biol Chem; 2012 Feb; 287(8):5600-14. PubMed ID: 22187427
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
